Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.65 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27013316 | 0.90 | CRBN (0.52) | CRBNDDB1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL23075766 | 0.84 | CRBN (0.63) | CRBNDDB1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL23075780 | 0.82 | CRBN (0.61) | CRBNDDB1 | |
| SCHEMBL27013297 | 0.80 | CRBN (0.49) | CRBNDDB1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL23067569 | 0.79 | CRBN (1.00) | CRBNDDB1OTUD7B | |
| SCHEMBL30465065 | 0.79 | CRBN (1.00) | CRBNDDB1OTUD7B | |
| SCHEMBL30242825 | 0.76 | CRBN (1.00) | CRBNDDB1 | |
| SCHEMBL21484140 | 0.76 | CRBN (1.00) | CRBNDDB1 | |
| SCHEMBL23075727 | 0.76 | CRBN (0.67) | CRBNDDB1ALDH1A1 | |
| SCHEMBL23075922 | 0.75 | CRBN (0.60) | CRBNDDB1OTUD7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11623929-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20210070763-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070763-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | CRBN 1/4885DDB1 153/4885ALDH1A1 1971/4885 |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | CRBN 1/4885DDB1 153/4885ALDH1A1 1971/4885 |
| US-11623929-B2 | Spirocyclic compounds | CRBN, XIAP, RBX1 | CRBN 1/4885DDB1 153/4885ALDH1A1 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.